Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01015560 · ClinicalTrials.gov registry record · Phase 2
S0916, MLN1202 in Treating Patients With Bone Metastases
A Phase 2 study of Metastatic Cancer and Unspecified Adult Solid Tumor, Protocol Specific, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 20
- Study locations
NCT01015560: Completed Phase 2 study of Metastatic Cancer and Unspecified Adult Solid Tumor, Protocol Specific, sponsored by SWOG Cancer Research Network.
NCT01015560 is a Phase 2 study of Metastatic Cancer and Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 44 participants, below the 443-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01015560, a Phase 2 study of Metastatic Cancer and Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Monoclonal antibodies, such MLN1202, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well MLN1202 works in treating patients with bone metastases.
Primary Outcome
Urinary n-telopeptide (uNTX) response is defined as a 25% reduction from baseline levels. Patients with missing response data were included as non-responders.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- GENETIC polymorphism analysis
- DRUG anti-CCR2 monoclonal antibody MLN1202
Study Locations (20)
Kansas
- Cancer Center of Kansas, PA - Chanute - Chanute
- Cancer Center of Kansas, PA - Dodge City - Dodge City
- Cancer Center of Kansas, PA - El Dorado - El Dorado
- Cancer Center of Kansas - Fort Scott - Fort Scott
- Cancer Center of Kansas-Independence - Independence
- Cancer Center of Kansas, PA - Kingman - Kingman
- Lawrence Memorial Hospital - Lawrence
- Cancer Center of Kansas, PA - Liberal - Liberal
- Cancer Center of Kansas, PA - Newton - Newton
- Cancer Center of Kansas, PA - Parsons - Parsons
- Cancer Center of Kansas, PA - Pratt - Pratt
- Cancer Center of Kansas, PA - Salina - Salina
- Cancer Center of Kansas, PA - Wellington - Wellington
- Associates in Womens Health, PA - North Review - Wichita
- Cancer Center of Kansas, PA - Medical Arts Tower - Wichita
California
- Glendale Memorial Hospital Comprehensive Cancer Center - Glendale
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
Indiana
- St. Francis Hospital and Health Centers - Beech Grove Campus - Beech Grove
- Reid Hospital & Health Care Services - Richmond
Illinois
- Cardinal Bernardin Cancer Center at Loyola University Medical Center - Maywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
What the finished NCT01015560 record still lists
NCT01015560 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 443-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01015560 names 20 study sites across 4 states, led by Kansas, California, Indiana.
Frequently Asked Questions
What is clinical trial NCT01015560 about?
NCT01015560 is a clinical study titled "S0916, MLN1202 in Treating Patients With Bone Metastases". RATIONALE: Monoclonal antibodies, such MLN1202, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well MLN1202 works i...
What is the current status of trial NCT01015560?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2010-03. Estimated completion is 2012-12.
What conditions does trial NCT01015560 study?
This clinical trial studies the following conditions: Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT01015560?
The interventions under investigation include: laboratory biomarker analysis (OTHER), polymorphism analysis (GENETIC), anti-CCR2 monoclonal antibody MLN1202 (DRUG).
Who is sponsoring clinical trial NCT01015560?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01015560 being conducted?
This trial has 20 study locations across California, Illinois, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01015560's enrollment target sits among peer trials
44 63rd of 109 higher than 46 of 109 other Metastatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Biomarkers to Detect Endocrine Therapy Resistance
RECRUITING · Phase 2
-
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
RECRUITING · Phase 2
-
Definitive Radiation for High-Risk Spine Metastases
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia